Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Prazepam→

Prazepam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2955-38-6
Molecular formula
C19H17ClN2O
Molecular weight
324.8 g/mol
Drug class
Benzodiazepine anxiolyticpositive allosteric modulator of GABAA receptors
Mechanism of action
Prazepam is metabolised to active benzodiazepine metabolites, including nordazepam, which positively modulate GABAA receptor activity at the benzodiazepine binding site and enhance GABA-mediated neuronal inhibition.
Indications / reported uses
  • Short-term treatment of anxiety disorders in countries where prazepam remains authorised; long-term use is limited by tolerance, dependence, sedation and withdrawal risk

Sources: NLM MeSH — Prazepam · PubMed — Prazepam benzodiazepine pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Prazepam Environmental Risk Assessment (ERA) (the Prazepam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.